Tumour angiogenesis: a novel therapeutic target in patients with malignant disease

Bibliography

• O'BYRNE KJ, DALGLEISH AG, BROWNING MJ, et al: The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer (2000) 36(2) :151–169.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Clinical applications of research on angiogenesis. N Engl. J. Med. (1995) 333:1757–1763.
   PubMed Web of Science ®Google Scholar
• HARRIS AL: Are angiostatin and endostatin cures for cancer. Lancet (1998) 351:1598–1599.
   PubMed Web of Science ®Google Scholar
• HOLMGREN L, O'REILLY MS, FOLKMAN J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppres-sion. Nature Med. (1995) 1:149–153.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• WEINSTAT-SASLOW DL, ZABRENETSKY VS, VAN HK, et al.: Transfection of thrombospondin 1 complementary DNA into human breast carcinoma line reduces primary growth, metastatic potential and angiogene-sis. Cancer Res. (1994) 54:6504–6511.
   PubMed Web of Science ®Google Scholar
• POLVERINI PJ, LEIBOVICH SJ: Induction of neovascu-larization in vivo and endothelial cell proliferation in vitro by tumour associated macrophages. Lab. Invest. (1984) 51:635–642.
   PubMed Web of Science ®Google Scholar
• LEEK RD, LEWIS CE, WHITEHOUSE R, et al.: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. (1996) 56:4625–4629.
   PubMed Web of Science ®Google Scholar
• COX G, JONES JL, WALKER RA, STEWARD WP, O'BYRNEKJ: Angiogenesis and non-small cell lung cancer. Lung Cancer (2000) 27:81–100.
   PubMed Web of Science ®Google Scholar
• O'BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKI A, et al.: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogene-sis in non-small cell lung cancer. Br. J Cancer (2000) 82:1427–1432.
   PubMed Web of Science ®Google Scholar
• COX G, STEWARD WP, O'BYRNE KJ: The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 54:169–179.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: Angiostatin induces and sustains dormancy of human primary tumours in mice. Nature Med. (1996) 2:689–692.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, BOEHM T, SHING Y, et al.: Endostatin: anendogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277–285.
   PubMed Web of Science ®Google Scholar
• DHANABAL M, RAMCHANDRAN R, WATERMAN MJ, et al.:Endostatin induces endothelial cell apoptosis. J Chem. (1999) 274:11721–11726.
   Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. ScL USA (1994) 26:4082–4085.
   Google Scholar
• KENYON BM, BROWNE F, D'AMATO RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64(6):971–8.
   PubMed Web of Science ®Google Scholar
• CHING LM, BROWNE WL, TCHERNEGOVSKI R, et al.: Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethyxanthenone-4-acetic acid: concomi-tant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br. J. Cancer (1998) 78:336–343.
   PubMed Web of Science ®Google Scholar
• SINGHAL S, MEHTA J, DESIKAN R, et al.: Antitumoractivity of thalidomide in refractory multiple myeloma. N Engl. J. Med. (1999) 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• EISEN T, BOSHOFF C, MAK I, et al.: Continuous low dose Thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J Cancer (2000) 82:812–817.
   PubMed Web of Science ®Google Scholar
• LITTLE RF, WYVILL KM, PLUDA JM, et al.: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin. Oncol. (2000) 18:2593–2602.
   PubMed Web of Science ®Google Scholar
• FINE HA, FIGG WD, JAECKLE K, et al.: Phase II trial of theantiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. j Clin. Oncol. (2000) 18:708–715.
   Web of Science ®Google Scholar
• INGBER D, FUJITA T, KISHIMOTO S, et al.: Syntheticanalogues of fumagillan that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348:555–557.
   PubMed Web of Science ®Google Scholar
• ABE J, ZHOU W, TAKUVVA et al.: A fumagillan derivativeangiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. (1994) 54 :3407–3412.
   PubMed Web of Science ®Google Scholar
• BUDSON AE, KO L, BRASEL C, BISCHOFF: The angiogenesis inhbibitor AGM-1 470 selectively increases E-selectin. Biochem. Biophys. Res. Commun. (1996) 225 (1):141–5.
   PubMed Web of Science ®Google Scholar
• SHIGEMATSU K, YASUHARA H, SHIGEMATSU H, et al.: Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF. Eur.J. Vasc. Endovasc. Surg. (1997) 14:290–298.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA H, SATOH H, KAMMA H, et al.: The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines. J. Exp. Ther. Oncol. (1996) 1:390-396.
   Google Scholar
• FUJIMOTO J, HORI M, ICHIGO S, et al.: Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and 0-(chloroacetyl-car b am oyl) fumagillol (TNP-470; AGM-1470). Cancer Lett. (1997) 113:187–194.
   PubMed Web of Science ®Google Scholar
• GRIFFITH EC, SU Z, TURK BE, et al.: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. (1997) 4:461–471.
   PubMed Web of Science ®Google Scholar
• KARAWADA Y, ISHIKURA H, KISHIMOTO T, et al.: Inhibi-tory effects of the antiangiogenic agent TNP-470 on establishment and growth of hematogenous metastasis of human pancreatic carcinoma in SCID beige mice in vivo. Pancreas (1997) 15:251–257.
   PubMed Web of Science ®Google Scholar
• KIDO A, TSUJIUCHI T, MORISHITA T, et al.: Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloroplatinum or the angiogenesis inhibitor AGM-1470. Jpn. J. Cancer Res. (1998) 89:1074–1081.
   PubMedGoogle Scholar
• WATSON JC, SUTANTO-WARD E, OSAKU M, et al.: Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats. Surgery (1999) 126:358–363.
   PubMed Web of Science ®Google Scholar
• KUDELKA AP, LEVY T, VERSCHRAEGEN CF, et al: A Phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. (1997) 3:1501–1505.
   PubMed Web of Science ®Google Scholar
• STADLER WM, KUZEL T, SHAPIRO C, et al.: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin. Oncol (1999) 17:2541.
   PubMed Web of Science ®Google Scholar
• BHARGAVA P, MARSHALL JL, RIZVI N, et al.: APhase land pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. an. Cancer Res. (1999) 5:1989–1999.
   Web of Science ®Google Scholar
• DEZUBE BJ, VON ROENN JH, HOLDEN-WILTSE J, et al.:Fumagillan analog in the treatment of Kaposi's sarcoma: a Phase I AIDS clinical trial group study. AIDS clinical trial group no. 215 team. J Clin. Oncol (1998) 16:1444–1449.
   PubMed Web of Science ®Google Scholar
• OFFODILE R, WALTON T, LEE M, et al: Regression ofmetastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumouri (1999) 85:51–53.
   PubMed Web of Science ®Google Scholar
• SCATENA M, ALMEIDA M, CHAISSON ML, et al.: NF-kapp aB mediates av133 integrin-induced endothe-lial cell survival. j Biol. Chem. (1998) 141:1083–1093.
   Google Scholar
• SOLDI R, MITOLA S, STRASLY M, et al.: Role ofalphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J (1999) 18:882–892.
   PubMed Web of Science ®Google Scholar
• HERMANN P, ARMANT M, BROWN E, et al.: The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. j Cell Biol. (1999) 1 44 (4):767–775.
   Web of Science ®Google Scholar
• COLEMAN KR, BRADEN GA, WILLINGHAM, MC, SANE DC: Vitaxin, a humanised monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ. Res. (1999) 84:1268–1276.
   PubMed Web of Science ®Google Scholar
• STROGARD CM, STUPACK DG, JONCZYK A, et al: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin. Invest. (1999) 103:47–54.
   PubMed Web of Science ®Google Scholar
• D'ANGELO G, MARTINI JF, IIRI T, et al.: 16K human prolactin inhibits vascular endothelial growth factor-induced activation of ras in capillary endothelial cells. Mol Endocrinol. (1999) 13:692–704.
   PubMed Web of Science ®Google Scholar
• SILLS AK, JR., WILLIAMS JI, TYLER BM, et al: Squalamine inhibits angiogenesis and solid tumour growth in vivo and perturbs embroyonic vasculature. Cancer Res. (1998) 58(13):2784–2792.
   PubMed Web of Science ®Google Scholar
• KAKEJI Y, TEICHER BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs (1997) 15:39–48.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, TERADA N, NISHIZAWA, PETROW V: Angiostatic activities of medroxyprogesterone acetate and its analogues. Int. J Cancer (1994) 56(3):393–399.
   PubMed Web of Science ®Google Scholar
• HORI Y, HU DE, YASUI K, SMITHER RL, GRESHAM GA, FAN TP: Differential effects of angiostatic steroids and dexamethasone on angiogenesis and cytokine levels in rat sponge implants. Br. J. Pharmacol. 11 8 (7):1584–1591.
   Google Scholar
• LIU J, RAZANI B, TANG S, et al: Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol. Chem. (1999) 274:15781–15785.
   PubMed Web of Science ®Google Scholar
• MAJEWSKI S, MARCZAK M, SZMURLO A, et al.: Retinoids,interferon alpha, 1, 25-dihydrox vitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harbouring tumor cell lines RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett. (1995) 89:117–124.
   PubMed Web of Science ®Google Scholar
• O'BYRNE KJ, HAN C, MITCHELL K, et al.: Phase II study of liarozole in advanced non-small cell lung cancer. Eur. J. Cancer (1998) 34:1463–1466.
   PubMed Web of Science ®Google Scholar
• YATSUNAMI J, TSURUTA N, FUKUNO Y, et al: Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells. Clin. Exp. Metastasis (1999) 17:119–124.
   PubMed Web of Science ®Google Scholar
• DE WILT JH, MANUSAMA ER, VAN ETTEN B, et al.: Nitric oxide synthase inhibition results in synergistic anti-tumour activity with mephalan and tumour necrosis factor alpha-based isolated limb perfusion. Br. J. Cancer (2000) 83:1176–1182.
   PubMed Web of Science ®Google Scholar
• ECKHARDT SG, BURRIS HA, ECKARDT JR, et al: A Phase Iclinical and pharmacokinetic study of the angiogene-sis inhibitor, tecogalan sodium. Ann. Oncol. (1996) 7:491–496.
   PubMed Web of Science ®Google Scholar
• LAU DH, XUE L, YOUNG LJ, BURKE PA, CHEUNG AT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularised transgenic breast cancer. Cancer Biother. Radiopharm. (1999) 14:31–36.
   PubMed Web of Science ®Google Scholar
• CLEMENTS MK, JONES CB, CUMMING M, DAOUD SS: Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol (1999) 44 :411–416.
   PubMed Web of Science ®Google Scholar
• O'BYRNE KJ, DOBBS N, PROPPER D, et al.: Vascularendothelial growth factor, platelet counts and renal cell cancer [Research letter]. Lancet (1 9 9 9) 353:1494-1495.
   Google Scholar
• COX G, JONES JL, WALKER RA, et al.: Angiogenesis andnon-small cell lung cancer. Lung Cancer (2000) 2781–100.
   Google Scholar
• FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endoc. Rev. (1997) 18:4–25.
   PubMed Web of Science ®Google Scholar
• WHITTLE C, GILLESPIE K, HARRISON R, MATHIESON PW, HARPER SJ: Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli and the identi-fication of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci. (1999) 97 :303–312.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J, et al.: Inhibition of vascularendothelial growth factor-induced angiogenesis suppresses tumour growth in viva Nature (1993) 3 62 :841–844.
   Google Scholar
• LIN P, SANKAR S, SHAN S, et al: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. (1998) 9(1)49–58.
   PubMedGoogle Scholar
• SKOBE M, ROCKWELL P, GOLDSTEIN N, et al.: Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. (1997) 3:1222–1227.
   PubMed Web of Science ®Google Scholar
• GORDON MS, TALPAZ M, MARGOLIN K, et al.: Phase I trialof recombinant humanised monoclonal anti-vascular endothelial growth factor (an ti-VEGF Mab) in patients (pts) with metastatic cancer. Proc. Am. Soc. Chn. Oncol. (1998) 17:210.
   Web of Science ®Google Scholar
• RYAN AM, EPPLER DB, HAGLER KE, et al: Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanised monoclonal antibody. Toxkol. Pathol. (1999) 27:78–86.
   PubMed Web of Science ®Google Scholar
• ANGELOV L, SALHIA B, RONCARI L, et al: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. CancerRes. (1999) 59:5536–5541.
   Web of Science ®Google Scholar
• FONG TA, SHAWVER LK, SUN L, et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1 /KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al: Antiangiogenictherapy targeting the tyrosine kinase receptor for vascular endothelial growth factor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• DREVS J, HOFMANN I, HUGENSCHMIDT H, et al.: Effectsof PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60:4819–4824.
   PubMed Web of Science ®Google Scholar
• XU L, YONEDA J, HERRERA C, WOOD J, KILLION JJ, FIDLER IJ: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. J Oncol. (2000) 16:445–454.
   PubMed Web of Science ®Google Scholar
• YANO S, HERBST RS, SHINOHARA H, et al.: Treatment for malignant pleural effusion of human lung adenocarci-noma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6:957–965.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, HARBISON MT, DAVIS DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936–1948.
   PubMed Web of Science ®Google Scholar
• FERRY D, HAMMOND L, RANSON M, et al: Intermittentoral Zd1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) shows evidence of good tolerability and activity: final results from a Phase II trial. Proc. Am. Soc. an. Oncol (2000) Abstract 5E.
   Google Scholar
• GLEAVE M, ELHILAH M, FRADET Y, et al. AND THE CANADIAN UROLOGIC ONCOLOGY GROUP: Interferon gamma-113 compared with placebo in metastatic renal cell carcinoma. N Engl. J Med. (1998) 338:1265–1271.
   PubMed Web of Science ®Google Scholar
• MEDICAL RESEARCH COUNCIL RENAL CANCER COLLABORATORS: Interferon -aand survival in metastatic renal carcinoma: early results of a random-ised controlled trial. Lancet (1999) 353:14–17.
   PubMed Web of Science ®Google Scholar
• NEGRIER S, ESCIDIER B, LASSET C, et al FOR THE GROUPEFRANCAIS D'IMMUNOTHERAPIE: Recombinant human interleukin-2, recombinant interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl. J Med. (1998) 388:1272–1278.
   Google Scholar
• HERNBERG M, PYRHC)NEN S, MUHONEN T: Regimens with or without interferon-a as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomised trials. j immunother. (1999) 22:145–154.
   PubMed Web of Science ®Google Scholar
• GROB JJ, DRENO B, DE LA SALMONIERE P, et al.: Random-ised trial of interferon-a2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 351:1905–1910.
   PubMed Web of Science ®Google Scholar
• COUGHLIN CM, SALHANY KE, WYSOCKA M, et al: In terleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. (1998) 101:1441–1452.
   PubMed Web of Science ®Google Scholar
• LASEK W, FELESZKO W, GOLAB J, et al: Antitumoureffects of the combination immunotherapy with IL-12 and tumour necrosis factor alpha in mice. Cancer Immunol. Immunother. (1997) 45:100–108.
   PubMed Web of Science ®Google Scholar
• COUGHLIN CM, SALHANY KE, GEE MS, et al: Tumor cellresponses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and anti-angiogenesis. Immunity (1998) 9:25–34.
   PubMed Web of Science ®Google Scholar
• SAMANIEGO F, MARKHAM PD, GENEDELMAN R, et al:Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergise to promote vascular permeability and KS lesion development. Am. J. Pathol. (1998)152:1433–1443.
   PubMed Web of Science ®Google Scholar
• COHEN T, NAHARI D, CEREM LW, NEUFELD G, LEVI BZ:Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. (1996) 271:736–41.
   PubMed Web of Science ®Google Scholar
• FUKUSHI J, MORISAKI T, SHONO T, et al.: Novel biological function of IL-4 and IL-13:formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem. Biophys. Res. CO1711711117. (1999) 250:444–448.
   Google Scholar
• FUJIEDA S, SUNAGA H, TSUZUKI H, et al.: IL-10 expres-sion is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett. (1999) 136:1–9.
   PubMed Web of Science ®Google Scholar
• JONES MK, ITANI RM, WANG H, et al: Activation of VEGFand Ras genes in gastric mucosa during angiogenic response to ethanol injury. Am. J Physiol (1999) 276:G1345–1355.
   PubMed Web of Science ®Google Scholar
• TANAKA H, NISHIDA K, SUGITA, YOSHIOKA T: Antitumor efficacy of hypothemycin, a new ras-signaling inhibitor. Jpn J Cancer Res. (1999) 90:1139–1145.
   PubMedGoogle Scholar
• BIANCO C, TORTORA G, BALDASSARRE G, et al.: 8-chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. Clin. Cancer Res. (1997) 3:439–444.
   PubMed Web of Science ®Google Scholar
• SAUNDERS MS, SALISBURY AJ, O'BYRNE KJ, et al.: A novel cyclic adenosine monophosphate analog induces hypercalcaemiaviaproductionof1,25-dihydroxyvitamin D in patients with solid tumors. J. Clin. Endocrinol. Metab. (1997) 82:4044–4048.
   PubMed Web of Science ®Google Scholar
• PROPPER DJ, SAUNDERS MS, SALISBURY A, et al.: APhase Istudy of a novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal and immunological effects. Clin. Cancer Res. (1999) 5:1682–1689.
   PubMed Web of Science ®Google Scholar
• DANESI R, AGEN C, BENELLI U, et al.: Inhibition ofexperimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin. Cancer Res. (1997) 3:265–272.
   PubMed Web of Science ®Google Scholar
• PATEL PC, BARRIE R, HILL N, et al.: Postreceptor signaltransduction mechanisms involved in octreotide induced inhibition of angiogenesis. Surgery (1994) 116:1148–1152.
   PubMed Web of Science ®Google Scholar
• REUBI J-C, HORISBERGER U, LAISSUE J: High density ofsomatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction Int. J Cancer (1994) 56:681–688.
   PubMed Web of Science ®Google Scholar
• PINSKI J, SCHALLY AV, HALMOS G, et al: Effects ofsomatostatin analog RC-160 and bombesin/gastrinre-leasing peptide antagonists on the growth of human small cell and nonsmall cell lung carcinomas in nude mice. Br. J. Cancer (1994) 70:886–892.
   PubMed Web of Science ®Google Scholar
• ALESSANDRO R, MASIERO L, LIOTTA LA, KOHN EC: The role of calcium in the regulation of invasion and angiogenesis. In Vivo (1996)10:153-160.
   Google Scholar
• KOHN EC, REED E, SAROSY G, et al: Clinical investiga-tion of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. (1999) 56:569–573.
   Google Scholar
• BAUER KS, FIGG WD, HAMILTON JM, et al: A pharma-cokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin. Cancer Res. (1999) 5:2324–2329.
   PubMed Web of Science ®Google Scholar
• BROWN P: Matrix metalloproteinase inhibitors. Breast Cancer Res. Treat. (1998) 52:125–136.
   PubMed Web of Science ®Google Scholar
• KONTTINEN YT, AINOLA M, VALLEALA H, et al: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58:691–697.
   PubMed Web of Science ®Google Scholar
• STEWARD WP: Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. (1999) 43 (Suppl.):S56–S60.
   Google Scholar
• COX G, JONES LJ, WALKER R, O'BYRNE KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin. Cancer Res. (2000) 6:2349–2355.
   PubMed Web of Science ®Google Scholar
• MACAULAY VM, O'BYRNE KJ, SAUNDERS MP, et al: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. (1999) 5:513–520.
   PubMed Web of Science ®Google Scholar
• SHALINSKY DR, BREKKEN J, ZOU H, et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:236–270.
   PubMed Web of Science ®Google Scholar
• SHALINSKY DR, BREKKEN J, ZOU H, et al: Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not daily dose, exposure or peak plasma concentrations. Invest. New Drugs. (1999) 16:303–313.
   Web of Science ®Google Scholar
• GILBERTSON-BEADLING S, POWERS EA, STAMP-COLE M, et al: The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother. Pharmacol. (1995) 36:418–424.
   PubMed Web of Science ®Google Scholar
• STUART R, HAWKINS P, MCCULLOCH T, et al.: A random-ised double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol (2000) 19. Abstract 929.
   Web of Science ®Google Scholar
• TEICHER BA, DUPUIS NP, ROBINSON MF, et al.: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol. Res. (1995) 7:237–243.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, DUPUIS NP, et al.: Potentiation of cytotoxic therapies by TNP470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res. Treat. (1995) 36:227–236.
   PubMed Web of Science ®Google Scholar
• HERBST RS, TAKEUCHI H, TEICHER BA: Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother. Pharmacol. (1998) 41:497–450.
   PubMed Web of Science ®Google Scholar
• SATOH H, ISHIKAWA H, FUJIMOTO M, et al.: Combined effects of TNP-470 and Tax ol in human non-small cell lung cancer cell lines. AntiCancer Res. (19 9 8) 18:1027-1030.
   Google Scholar
• SZEPESHAZI K, LAPIS K, SCHALLY AV: Effect of combina-tion treatment with analogs of luteinizing hormone-releasing hormone (LI-1-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int. J Cancer (1991) 49:260–266.
   PubMed Web of Science ®Google Scholar
• THOMAS F, BOURGEOIS E, POUPON MF: Additive inhibi-tory effects of cyclophosphamide (CPM) and of a somatostatin analogue lanreotide (Ian) on the growth of a small cell lung cancer (SCLC) xenograft. Proc. Am. Assoc. Clin. Oncol. (1992) 11. Abstract 1036.
   Google Scholar
• WECKBECKER G, RAULF F, TOLCSVAI L, BRUNS C: Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion (1996) 57 (Suppl. 0:22–28.
   Google Scholar
• BRUNS CJ, SOLORZANO CC, HARBISON MT, et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. (2000) 60:2926–2935.
   PubMed Web of Science ®Google Scholar
• KLEMENT G, BARUCHEL S, RAK J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regres-sion without overt toxicity. J. Clin. Invest. (2000) 105 (8):R15–24.
   PubMed Web of Science ®Google Scholar
• HANNINEN EL, KIRCHNER H, ATZPODIEN J: Interleuken-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol (1996) 155:19–25.
   PubMed Web of Science ®Google Scholar
• GASPARINI G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs (1999) 58:17–38.
   PubMed Web of Science ®Google Scholar
• HUANG X, MOLEMA G, KING S, et al.: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (1997) 275:547–550.
   PubMed Web of Science ®Google Scholar
• TSUNODA S, OHIZUMI I, MATSUI J, et al: Specific binding of IM-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy. Br]. Cancer (1999) 81:1155–1161.
   PubMed Web of Science ®Google Scholar
• KONG H-L, CRYSTAL RG: Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. (1998) 90:273–284.
   PubMed Web of Science ®Google Scholar
• LAU KKW, BICKNELL R: Antiangiogenic gene therapy. Gene Ther. (1999) 6:1793–1795.
   PubMed Web of Science ®Google Scholar
• MILLAUER B, SHAWVER LK, PLATE KH, et al: Glioblas-toma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature (1994) 367:576–579.
   PubMed Web of Science ®Google Scholar
• SALEH M, STACKER SA, WILKS AF, et al: Inhibition of growth of C6 glioma cells in vivo by expression of an tisense vascular endothelial growth factor sequence. Cancer Res. (1996) 56:393–401.
   PubMed Web of Science ®Google Scholar
• IM SA, GOMEZ-MANZANO, FUEYO J, et al.: Antiangio-genesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. (1999) 59:895–900.
   PubMed Web of Science ®Google Scholar
• LIN P, SANKA S, SHAN S, et al: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell. Growth Diff (1998) 9:49–58.
   PubMedGoogle Scholar
• GUO N, KRUTZSCH HC, INMAN JK, ROBERTS DD: Thrombospondin 1 and Type I repeat peptides of thrombospondin I specifically induce apoptosis of endothelial cells. Cancer Res. (1997) 57:1735–1742.
   PubMed Web of Science ®Google Scholar
• CLAESSON-WELSH L, WELSH M, ITO N, et al: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin binding motif RGD. Proc. Natl. Acad. Sci. USA (1988) 95:5579–5583.
   Google Scholar
• TANAKA T, CAO Y, FOLKMAN J, FINE HA: Viral vector-targeted antiangiogenic gene therapy utilising an angiostatin complementary DNA. Cancer Res. (1998) 58:3362–3369.
   PubMed Web of Science ®Google Scholar
• TANAKA T, MANOME Y, WEN P, et al: Viral vector mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med. (1997) 3:437–442.
   PubMed Web of Science ®Google Scholar
• BLEZINGER P, WANG J, GONDO M, et al.: Systemic inhibi-tion of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotechnol. (1999) 17:343–348.
   PubMed Web of Science ®Google Scholar
• LIN P, BUXTON JA, ACHESON A, et al: Antiangiogenic gene therapy targets the endothelial-specific receptor tyrosine kinase tie2. Proc. Natl. Acad. Sci. USA (1998) 95:8829–8834.
   PubMed Web of Science ®Google Scholar
• LIU Y, THOR A, SHTIVELMAN Y et al: Systemic gene delivery expand the repertoire of effective antiangio-genic agents. J. Biol. Chem. (1999) 274:13338–13344.
   PubMed Web of Science ®Google Scholar
• BERGERS G, JAVAHERIAN K, LO KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis. Science (1999) 284:808–812.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, KAWAMATA H, FUJIMOTO K, OYASU R: Angiogenesis inhibitor TNP-470 suppresses tumorige-nesis in rat urinary bladder. j Uroi. (1997) 157:683–688.
   PubMed Web of Science ®Google Scholar
• FOTSIS T, PEPPER MS, MONTESANO R, et al.: Phytoestro-gens and inhibition of angiogenesis. Baillieres Clin. Endocrinol. Metab. (1998) 12:649–666.
   PubMed Web of Science ®Google Scholar
• ZHOU JR, GUGGER ET, TANAKA et al.: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumour angiogenesis in mice. J. Nutr. (1999) 129:1628–1635.
   PubMed Web of Science ®Google Scholar
• TATSUTA M, IISHI H, BABA M, et al: Attenuation by genistein of sodium chloride enhanced gastric carcinogen esis induced by N-methyl-N'-nitro-N--nitrosoguanidine in Wister rats. Int. J. Cancer (1999) 80:396–399.
   PubMed Web of Science ®Google Scholar
• HUANG M-T, LOU Y-R, MAW et al.: Inhibitory effects of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. Cancer Res. (1994) 54:5841–5887.
   PubMed Web of Science ®Google Scholar
• ARBISER JL, KLAUBER N, ROHAN R, et al: Cur cumin is an in vivo inhibitor of angiogenesis. Mol. Med. (1998) 4:376–383.
   PubMed Web of Science ®Google Scholar
• CASTONGUAY A, RIOUX N: Inhibition of lung tumorige-nesis by sulindac: comparison of 2 experimental protocols. Carcinogenesis (1997) 18:491–496.
   PubMed Web of Science ®Google Scholar
• PERKINS TM, SHKLAR G: Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg. (1982) 53:170–178.
   PubMedGoogle Scholar
• MCCORMICK DL, MADIGAN MJ, MOON RC: Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. (1985) 45:1803–1808.
   PubMed Web of Science ®Google Scholar
• SAMAHA HS, KELLOFF GJ, STEELE V: Modulation of apoptosis by sulindac, curcumin, phenylethy1-3-methylcaffeate and 6-phenylhexyl isocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. (1997) 57:1301–1305.
   PubMed Web of Science ®Google Scholar
• GIARDIELLO FM, HAMILTON SR, KRUSH AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl. J. Med. (1993) 328:1313–1316.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RK, et al: The effect of celecoxib, a cyclooygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. (2000) 342(26)1946–1952.
   PubMed Web of Science ®Google Scholar
• THUN MJ, NAMBOODIN MM, HEATH CW, JR.: Aspirin use and reduced risk of fatal colon cancer. N Engl. J Med. (1991) 325:1593–1596.
   PubMed Web of Science ®Google Scholar
• GIOVANNUCCI E, EGAN KM, HUNTER DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl. J. Med. (1995) 333:609–614.
   PubMed Web of Science ®Google Scholar
• FUNKHOUSER EM, SHARP PH: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76:1116–1119.
   PubMed Web of Science ®Google Scholar
• TSUJI M, KAWANO S, TSUJI S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 94(2):271.
   Google Scholar
• INTERNATIONAL INTERFERON-a HEPATOCELLULAR CARCINOMA STUDY GROUP: Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet (1 9 9 8) 351:1535-1539.
   Google Scholar
• GAGLIARDI AR, HENNIG B, COLLINS DC: Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. AntiCancer Res. (1996) 16:1101–1106.
   PubMed Web of Science ®Google Scholar
• LINDNER DJ, BORDEN EC: Effects of tamoxifen and interferon-I3 or the combination on tumor-induced angiogenesis. Int. J Cancer (1997) 71:456–461.
   PubMed Web of Science ®Google Scholar
• HADDOCK G, HARRISON DJ, CARTER DC: The effect of the somatostatin analogue SMS 201-995 on experi-mental pancreatic carcinogenesis in the Syrian golden hamster. Carcinogenesis (1991) 12:1103–1107.
   PubMed Web of Science ®Google Scholar
• SZENDE B, JUHASZ E, LAPIS K, SCHALLY AV: Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urol. Res. (1992) 20:383–386.
   PubMed Web of Science ®Google Scholar
• FISHER B, CONSTANTINO JP, WICKERHAM DL, et al: Tamoxifen for the prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. (1998) 90:1371–1388.
   PubMed Web of Science ®Google Scholar
• JORDAN VC, MORROW M: Tamoxifen, raloxifene and the prevention of breast cancer. Endocr. Rev. (1999) 20:253–278.
   PubMed Web of Science ®Google Scholar
• LEVER AF, HOLE DJ, GILLIS CR, et al: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer Lancet (1998) 352:179–84.
   PubMed Web of Science ®Google Scholar
• GATELY S, TWARDOWSKI P, STACK MS, et al: The mechanism of cancer mediated conversion of plasmi-nogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. ScI USA (1997) 94:10868–10872.
   PubMed Web of Science ®Google Scholar
• VOLPERT OV, WARD WF, LINGEN MW, et al: Captopril inhibits angiogenesis and slows the growth of experi-mental tumors in rats. J. Clin. Invest. (1996) 98:671–679.
   PubMed Web of Science ®Google Scholar
• JONES M, PHILLIP T, PALMER P, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother. (1993) 8:275–288.
   PubMedGoogle Scholar
• BRAYBROOKE J, O'BYRNE KJ, PROPPER DJ, et al.: APhase II study of razoxane, an anti-angiogenic topoisomerase II inhibitor, in renal cell cancer. Clin. Cancer Res. (2001) 6:4697–4704.
   Web of Science ®Google Scholar
• BICKNELL R, HARRIS AL: Mechanisms and therapeutic implications of angiogenesis. CUIT. Opin. Oncol (1996) 8:60–65.
   PubMed Web of Science ®Google Scholar
• DELORME S, KNOPP MV: Non-invasive vascular imaging: assessing tumour vascularity. Eur. Radio]. (1998) 8:517–527.
   PubMed Web of Science ®Google Scholar
• VAN DIJKE CF, BRASCH RC, ROBERTS TP, et al.Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology (1996) 198 (3):813–818.
   PubMed Web of Science ®Google Scholar
• STOMPER PC, WINSTON JS, HERMAN S, et al.: Angiogene-sis and dynamic MR imaging gadolinium enhance-ment of malignant and benign breast lesions. Breast Cancer Res. Treat. (1997) 45:39–46.
   PubMed Web of Science ®Google Scholar
• BRASCH R, PHAM C, SHAMES D, et al.: Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging (1997) 7:68–74.
   PubMed Web of Science ®Google Scholar
• CREW J, O'BRIEN T, BICKNELL R, et al.: Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J. Urol. (1999) 161: 799–804.
   Google Scholar
• DIRIX LY, VERMEULEN PB, PAWINSKI A, et al.: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer (1997) 76:238–243.
   PubMed Web of Science ®Google Scholar
• O'BRIEN TS, SMITH K, CRANSTON D, et al.: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br. J. Urol (1995) 76:311–314.
   PubMedGoogle Scholar
• STEPHENS RW, PEDERSEN AN, NIELSEN HJ, et al.: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem. (1997) 43:1868–1876.
   PubMed Web of Science ®Google Scholar
• KOCH AE, HALLORAN MM, HASKELL CJ, et al.: Angiogene-sis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature (1995) 376 :517–519.
   PubMed Web of Science ®Google Scholar
• BROCK TA, DVORAK HF, SENGER DR: Tumour secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothe-lial cells. Am. J. Pathol. (1991) 138:213–221.
   PubMed Web of Science ®Google Scholar